Artivion’s (AORT) “Buy” Rating Reiterated at Needham & Company LLC

Needham & Company LLC reaffirmed their buy rating on shares of Artivion (NYSE:AORT) in a report published on Tuesday morning,Benzinga reports. The firm currently has a $34.00 price objective on the stock.

Other research analysts have also issued research reports about the company. JMP Securities restated a “market outperform” rating and set a $33.00 price objective on shares of Artivion in a research report on Tuesday, December 10th. Oppenheimer increased their price objective on shares of Artivion from $30.00 to $32.00 and gave the stock an “outperform” rating in a research report on Friday, November 8th. Five investment analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock presently has an average rating of “Buy” and a consensus price target of $31.80.

Artivion Price Performance

Shares of Artivion stock opened at $31.38 on Tuesday. The company has a market capitalization of $1.32 billion, a price-to-earnings ratio of -1,568.75 and a beta of 1.74. The company has a quick ratio of 1.33, a current ratio of 1.88 and a debt-to-equity ratio of 0.71. The stock’s 50-day simple moving average is $29.40 and its 200-day simple moving average is $27.41. Artivion has a 52 week low of $16.48 and a 52 week high of $32.33.

Insider Buying and Selling at Artivion

In other Artivion news, VP Andrew M. Green sold 7,618 shares of the business’s stock in a transaction that occurred on Wednesday, December 4th. The shares were sold at an average price of $30.00, for a total transaction of $228,540.00. Following the sale, the vice president now owns 33,503 shares of the company’s stock, valued at approximately $1,005,090. The trade was a 18.53 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, SVP Jean F. Holloway sold 8,070 shares of the business’s stock in a transaction on Wednesday, December 11th. The shares were sold at an average price of $30.12, for a total transaction of $243,068.40. Following the sale, the senior vice president now directly owns 153,862 shares in the company, valued at $4,634,323.44. This trade represents a 4.98 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 20,017 shares of company stock worth $600,007 over the last quarter. Insiders own 8.10% of the company’s stock.

Hedge Funds Weigh In On Artivion

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in AORT. Wellington Management Group LLP lifted its holdings in shares of Artivion by 2.9% during the third quarter. Wellington Management Group LLP now owns 1,656,264 shares of the company’s stock worth $44,090,000 after purchasing an additional 46,267 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its stake in Artivion by 58.4% during the 3rd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 340,887 shares of the company’s stock valued at $9,074,000 after acquiring an additional 125,668 shares during the period. Lord Abbett & CO. LLC purchased a new stake in Artivion in the third quarter valued at $5,798,000. Tidal Investments LLC grew its holdings in Artivion by 602.2% during the third quarter. Tidal Investments LLC now owns 157,002 shares of the company’s stock worth $4,179,000 after acquiring an additional 134,642 shares during the period. Finally, Sio Capital Management LLC purchased a new position in shares of Artivion during the 3rd quarter valued at approximately $3,226,000. Hedge funds and other institutional investors own 86.37% of the company’s stock.

Artivion Company Profile

Artivion, Inc manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company provides BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins for cardiac, vascular, neurologic, and pulmonary procedures; cardiac preservation services; PhotoFix, a bovine pericardial patch; and aortic arch stent grafts including E-vita Open Plus and E-vita Open Neo.